Haematologica (Jul 2007)

Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen

  • Vikram Mathews,
  • Maria Thomas,
  • Vivi M Srivastava,
  • Biju George,
  • Alok Srivastava,
  • Mammen Chandy

DOI
https://doi.org/10.3324/haematol.10802
Journal volume & issue
Vol. 92, no. 7

Abstract

Read online

Ninety-eight newly diagnosed cases of PML-RARαpositive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARαisoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.